The Journal of Clinical and Experimental Hematopathology, published by the Japanese Society of Lymphoreticular Tissue Research, is a vital resource dedicated to advancing the field of hematopathology. With an impressive Open Access model since 2019, this journal provides researchers, clinicians, and students from around the world with unfettered access to cutting-edge research and developments in hematology and pathophysiology. Based in Japan, it has established a prominent reputation in the academic community, boasting a Q3 quartile ranking in Hematology and Q1 rankings in both Medicine (Miscellaneous) and Pathophysiology as of 2023. With its innovative contributions and high visibility, the journal not only fosters scholarly discourse but also impacts clinical practices, making it an essential publication for anyone interested in the complexities of hematologic disorders. For submissions and further inquiries, the journal is located at Nagoya University Graduate School of Medicine, Japan.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

MODERN PATHOLOGY is a premier journal in the field of pathology and forensic medicine, published by Elsevier Science Inc. With an impressive impact factor that places it in the top 1st quartile (Q1) for 2023, and a remarkable rank of 5 out of 208 in its category according to Scopus, it serves as a vital resource for researchers, professionals, and students alike. Established in 1988, the journal focuses on the latest advancements in diagnostic pathology, molecular pathology, and related fields, providing a platform for innovative research that drives the discipline forward. Although it does not operate under an open access model, readers can expect rigorously peer-reviewed publications that contribute to the growing body of knowledge in pathology. With a continuous commitment to excellence and relevance, MODERN PATHOLOGY remains a fundamental avenue for disseminating high-quality scientific research globally, facilitating the growth and development of its field.

NEURO-ONCOLOGY, a leading journal published by OXFORD UNIVERSIT PRESS INC, is at the forefront of research in the intersection of neurology and oncology, with contributions spanning from 1999 to 2024. With a recognized impact reflected in its strong ranking, holding Q1 status in Cancer Research, Neurology (Clinical), and Oncology categories, NEURO-ONCOLOGY provides a vital platform for the dissemination of groundbreaking studies and advancements in brain tumor research and treatment. The journal ranks impressively within the 99th percentile in clinical neurology and 96th percentile in oncology, highlighting its significance and influence within the field. Accessible through institutional subscriptions, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to stay informed of the latest developments, therapeutic strategies, and scientific discussions in neuro-oncology.

Head & Neck Pathology is a leading journal dedicated to advancing the study of pathologies affecting the head and neck region, published by Springer. With an ISSN of 1936-055X and E-ISSN of 1936-0568, this journal serves as a vital resource for the dissemination of research in oncology, otorhinolaryngology, and pathology, achieving impressive rankings of Q2 in Oncology and Q1 in both Otorhinolaryngology and Pathology & Forensic Medicine in 2023. Since its inception in 2007, Head & Neck Pathology has continued to provide a platform for innovative research findings, case studies, and reviews, fostering a deeper understanding of head and neck diseases. The journal's commitment to excellence is reflected in its rigorous peer-review process and accessibility through various academic platforms. Researchers, clinicians, and students will find valuable insights and knowledge that can enhance clinical practice and improve patient outcomes in the dynamic field of head and neck pathology.

ADVANCES IN ANATOMIC PATHOLOGY is a leading peer-reviewed journal dedicated to the field of anatomical pathology, published by LIPPINCOTT WILLIAMS & WILKINS. With an impressive impact factor and consistent ranking in the Q1 category for both Anatomy and Pathology and Forensic Medicine, it serves as an essential resource for researchers, clinicians, and students alike. The journal has been a critical platform for disseminating significant findings and advancements in the discipline since its inception in 1996, boasting Scopus rankings of #1 in Anatomy and #11 in Pathology. While it does not provide open access, it maintains rigorous standards in the selection of articles, ensuring that published research reflects the latest developments and techniques in the field. As we look toward 2024 and beyond, ADVANCES IN ANATOMIC PATHOLOGY remains committed to advancing the science of pathology, fostering innovation, and enhancing clinical practice through impactful research.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.